Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Therapeutics Ltd. (ENLV) generates news at the intersection of clinical-stage immunotherapy and digital asset treasury management. Company announcements highlight progress in the development of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, and its application in moderate-to-severe knee osteoarthritis. Press releases have detailed positive three- and six-month topline data from the ENX-CL-05-001 Phase I/II trial, including clinically meaningful and statistically significant reductions in pain and improvements in function in age-related primary knee osteoarthritis patients.
Investors following ENLV news will also see updates on Enlivex’s adoption of a digital asset treasury strategy centered on the RAIN token. The company reports that RAIN is the primary asset of its digital asset treasury and describes RAIN as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. News items have covered a large private placement intended to fund RAIN token accumulation, an exclusive option agreement to purchase RAIN tokens, and the listing of RAIN on major cryptocurrency exchanges such as KuCoin.
Additional ENLV coverage includes SEC-related disclosures, board and governance changes, shareholder communications, and participation in scientific conferences and investor events. Readers can expect articles on clinical data presentations, new patents related to Allocetra™ in osteoarthritis, shareholder letters outlining strategic roadmaps, and virtual webinars or fireside chats with company leadership and external experts. For those tracking both biotechnology developments in knee osteoarthritis and corporate activity around a RAIN-focused digital asset treasury, the Enlivex news feed provides a consolidated view of the company’s key milestones and strategic decisions.
Enlivex Therapeutics has appointed Dr. Einat Galamidi as Vice President, Medical. Dr. Galamidi brings a decade of clinical development experience from Gamida Cell, where she led the development of omidubicel, a cell therapy for blood cancers. This therapy has recently initiated a Biologics License Application process with the FDA. Dr. Galamidi aims to leverage her expertise in advancing Enlivex's Allocetra program, which targets sepsis and COVID-19, among other conditions, to restore macrophage homeostasis and address unmet medical needs.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022. Management will engage in a panel discussion titled "Innovative Approaches to Cell Therapy for Oncology" on January 7 at 8:30 AM ET. The event aims to highlight innovative biotechnology and therapeutic advancements, focusing on unmet medical needs in oncology. Enlivex is advancing Allocetra™, a universal cell therapy designed to reprogram macrophages, targeting serious conditions like solid cancers and sepsis, aiming to restore immune balance.
Enlivex Therapeutics Ltd. announced that Greece’s National Organization of Medicines has approved the expansion of its Phase IIb trial for AllocetraTM in severe COVID-19 patients to additional sites. The trial aims to enroll up to 152 patients and assess the drug's safety and efficacy alongside standard treatment. Previously reported trials indicated a 0% mortality rate and a 90.5% recovery rate in severe cases. Top-line data is anticipated in late 2022 or Q1 2023. The company aims to expand its clinical trials throughout Europe.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its Phase II trial for AllocetraTM in pneumonia-associated sepsis has received approval for expansion into Greece. The trial, already active in Israel and Spain, aims to enroll 120 to 160 patients across four cohorts, assessing safety and efficacy over a 28-day follow-up. Previous Phase Ib results indicated a positive safety profile and improved clinical outcomes. Interim results are expected in the first half of 2022, with top-line data anticipated by year-end 2022.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the U.S. Patent and Trademark Office granted a notice of allowance for a new patent covering AllocetraTM, aimed at treating sepsis patients. The patent is expected to be issued in early 2022, extending intellectual property protection until at least 2036. Enlivex is conducting a Phase II trial of AllocetraTM in pneumonia-associated sepsis, with interim results anticipated mid-2022 and top-line data by year-end 2022. Additional programs target COVID-19 and solid tumors.
Enlivex Therapeutics announced several significant advancements as of November 22, 2021. They have initiated dosing in a Phase IIb trial for AllocetraTM in severe COVID-19 patients and received authorization to expand trials into Spain. A new cGMP manufacturing facility is currently in the design phase to support future needs. Financially, for Q3 2021, Enlivex reported a net loss of $3.424 million, increasing from $2.125 million year-over-year, while holding $87.6 million in cash and equivalents, sufficient to fund operations through 2023.
Enlivex Therapeutics has received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) to expand its Phase IIb trial of Allocetra in treating severe and critical COVID-19 patients with ARDS to Spain. The trial aims to enroll up to 152 patients and assess safety and efficacy against standard treatment. Previous trials reported a 0% mortality rate and 90.5% recovery in treated patients. CEO Oren Hershkovitz highlighted the importance of this expansion for their regulatory strategy, reinforcing the potential of Allocetra across various conditions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the expansion of its Phase II trial of AllocetraTM to clinical sites in Spain. The trial aims to enroll 120 to 160 patients with pneumonia-associated sepsis. It will assess the safety and efficacy of AllocetraTM compared to a placebo. Previous positive results from a Phase Ib trial indicate significant improvements in clinical outcomes for sepsis patients treated with AllocetraTM.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the publication of a significant peer-reviewed paper led by its Chief Scientific Officer, Prof. Dror Mevorach, in The New England Journal of Medicine. This paper examines myocarditis following the BNT162b2 mRNA vaccine against COVID-19 in Israel. The publication reflects the company's research collaboration with prestigious institutions and highlights the growing recognition of their work in immunotherapy. CEO Oren Hershkovitz praised Prof. Mevorach's expertise and its importance in the development of Allocetra, a therapy aimed at treating severe conditions like sepsis and COVID-19.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Israeli Patent Office has granted a notice of allowance for a patent application covering AllocetraTM, an immunotherapy product targeting various diseases, including sepsis and COVID-19. This patent will provide intellectual property protection in Israel until at least 2037. AllocetraTM is designed to reprogram macrophages to restore their homeostatic state, potentially offering new treatment options for life-threatening conditions. The patent issuance is expected in Q1 2022.